|
David Khayat (born August 27, 1956) is a French oncologist. Head of the Department of Medical Oncology at the Pitié-Salpêtrière Hospital since 1990, he is also Professor of oncology at the University Pierre and Marie Curie and adjunct Professor at the MD Anderson Cancer Center in Houston, Texas. He was elected at the American Society of Clinical Oncology board in 2013.〔http://connection.asco.org/Login.aspx?returnurl=%2fMagazine%2fArticle%2fID%2f3733%2fASCO-Announces-Newly-Elected-Leaders.aspx〕 Organiser of the World Summit against Cancer at the UNESCO, he initiated the Charter of Paris against Cancer and headed the French Cancer National Institute between April 2004 and September 2006. He is its Honorary President now. Professor Khayat is the founder and the President of the Foundation AVEC,〔http://www.fondation-avec.org〕 a non-profit organisation declared of public utility since 2013. ==Education== David Khayat〔http://www.davidkhayat.fr/〕 made his medical studies at the University of Nice from 1974 to 1980. Over the next five years he undertook internship and residency training at hospitals in Paris, and moved towards the field of oncology. Later, during his formal studies in oncology, he attained a Master of Science in tumor immunology. Part of these studies were conducted in Israel with Professor Isaac Witz, at the University of Tel Aviv. Then, back to France in 1985, he finished his training in medical oncology and got his MD and became board certified in oncology the same year. In 1986, David Khayat went to the Mount Sinaï school medicine in New York (Department of Biochemistry, J.C Unkeless) and got his Ph. D in tumor immunology in 1988 at the University Pierre and Marie Curie in Paris. During his Ph. D, he has been working on the identification and purification of the soluble Fc receptors both, in mouse and human sera, and set up a new ELISA sandwich assay for the detection and the quantitive dosage of this soluble molecule. He demonstrated the relationship between the release of this soluble receptor in human serum (called also immunoglobuling binding factors IBF) and different pathologic conditions (AIDS, ITP …). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「David Khayat」の詳細全文を読む スポンサード リンク
|